Sign In
Search Icon
Menu Icon

COVID-19 Therapeutics Thresholds, Orders, and Replenishment

COVID-19 Oral Antivirals Transitioning to Commercial Marketplace

The federal government is transitioning COVID-19 oral antiviral treatments Paxlovid (nirmatrelvir packaged with ritonavir) and Lagevrio (molnupiravir) to the commercial market. To learn about upcoming milestones and timelines, see Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program.

See Important Dates

Ordering Paxlovid and Lagevrio

Paxlovid and Lagevrio are available for purchase via the commercial market as of November 1, 2023.  As part of the transition of COVID-19 therapeutics distribution to the commercial marketplace, ASPR has implemented the following protocols in accordance with its Sunsetting the U.S. Government COVID-19 Therapeutics Distribution Program:

  • Lagevrio ordering through the USG stopped on November 10, 2023.
  • Paxlovid ordering through the USG stopped on December 15, 2023.

For more information about ordering, reporting, and using your supplies, please visit:

Federal Entities

Federal entities may continue to order Paxlovid from the U.S. government (USG) supply. Federal entities, excluding the Department of Defense and Veterans Affairs, may continue to order Lagevrio until supply is depleted. Ordering occurs through Health Partner Ordering Portal (HPOP)

State and Territory Officials

Jurisdictions and other partners should work with their providers/sites to deplete the USG supply in the field and replace inventory with commercial supply as needed.

Reporting Administration of Paxlovid and Lagevrio

The federal government tracks the amount of COVID-19 therapeutic products ordered and administered through the HPOP portal, monitoring product availability and administration of the USG-distributed products for each state or territory.

All disposal and returns of the USG-procured products need to be recorded in HPOP.

COVID-19 Therapeutics Summary: USG Supplied Therapeutics Available for Patient Use1

December 17, 2021 –June 30, 2024

Therapeutic  Delivered Administered
22,599,214 14,892,005

States, territories, and federal entities, including HRSA
Includes EUA Paxlovid and EUA Renal Paxlovid for all central partners and NDA-labeled Paxlovid and NDA-labeled Renal Paxlovid ordered by Federal Entities.

  • Data Source: Tiberius, Updated 07/01/2024
  • Data through Sunday, 6/30/2024

COVID-19 Therapeutics Summary: Previous USG Supplied Therapeutics No Longer in Use

2020 – 2023

(currently not in use*)
Date of
First Issue
Date of
Last Distribution
Evusheld (300mg doses) December 8, 2021 January 26, 2023 1,032,156 738,936
Bebtelovimab February 11, 2022 November 30, 2022 739,889 624,633
Sotrovimab May 26, 2021 April 5, 2022 706,692 302,209
Bamlanivimab/Etesevimab February 9, 2021 January 24, 2022 642,125 610,753
REGEN-COV November 21, 2020 January 24, 2022 2,878,138 2,078,587
Bamlanivimab** November 9, 2020 March 2, 2021 664,691 N.A.

*Products are not currently authorized for use in any U.S region due to high frequency of SARS-CoV-2 subvariants to which these therapeutics are unlikely to be effective.

**EUA was revoked for bamlanivimab when administered alone; courses administered data are not available at this time.

Prior COVID-19 Therapeutic Product Efforts

Date Range Threshold/Distribution/Allocation by Jurisdiction
February 2024-June2024
Administered Amounts by Jurisdiction
September 2022-December 2023
Cumulative COVID-19 Therapeutics Delivered and Administered Amounts by Jurisdiction​
April 25, 2022 - November 26, 2023
COVID-19 Therapeutics Threshold Determinations
September 13, 2021 - April 24, 2022 COVID-19 Therapeutics Distribution
November 9, 2020 - March 2, 2021 Bamlanivimab Distribution
November 24, 2020 - February 2, 2021 REGEN-COV Distribution
July 6, 2020 - October 4, 2020 Allocation of Commercial Veklury (Remdesivir) (PDF)
May 4, 2020 - June 29, 2020
Allocation of Donated Veklury (Remdesivir)